Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Acromegaly 2Sarcoma 1Prostatic Neoplasms 1Pituitary Neoplasms 1Lung Neoplasms 1Hyperplasia 1Fibrous Dysplasia, Polyostotic 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Adenoma 1

Interventions

Colonoscopy 19Water 3Aspirin 3Ursodeoxycholic Acid 2Sunitinib 2Occult Blood 2Narrow Band Imaging 2Folic Acid 2Endoscopic Mucosal Resection 2Calcium Carbonate 2pegvisomant 1gadolinium ethoxybenzyl DTPA 1defactinib 1S-Adenosylmethionine 1Reference Standards 1Polyethylene Glycols 1Octreotide 1Methods 1Mesalamine 1Mass Screening 1Injections 1Indocyanine Green 1Gastroscopy 1Endoscopy 1Early Detection of Cancer 1Drug Evaluation 1Diet, Fat-Restricted 1Diagnostic Tests, Routine 1Cholecystectomy 1Cholecalciferol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma × pegvisomant × Clear all
NCT00017927 2008-03-04

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

National Institutes of Health Clinical Center (CC)

Phase 3 Completed
10 enrolled

Acromegaly, Adenoma, Fibrous Dysplasia, Polyostotic, Hyperplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡